About

Dr. Gabriel is currently serving as Chief Executive Officer, CEO, for BioMedInnovations, LLC. Denver, North Carolina. Most recently he operated as Vice President of Equity Research at H.C. Wainwright & Co., covering the most relevant HealthCare biotech firms with a focus on Respiratory, Allergenic and Immunologic indications. Previously, he served as Vice President of Scientific Search and Alliance Management at Nivalis Therapeutics, a clinical-stage biotechnology company focused on developing transformational medications for patients with Cystic Fibrosis, (CF). In that role Dr. Gabriel was responsible for overseeing the preclinical development of Nivalis products as well as conducting diligence and evaluation of other products and potential collaborators (Biotech and Academic) in the CF space. During his tenure with Nivalis, Dr. Gabriel was a fundamental part of the Executive team that successfully completed both a cross-over and IPO round of funding as well as an IND submission. Prior to Nivalis Dr. Gabriel was a Professor of Pediatrics, at the University of North Carolina at Chapel Hill and Director of the Cystic Fibrosis Molecular Therapy and Correction Core. He also served as Co-chairman and founding member of the Cystic Fibrosis Foundation, CFF, Mucociliary Clearance Consortium.